Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 September 2017 | By Zachary Brennan
The World Health Organization (WHO) announced Tuesday that in October it will launch a pilot project for prequalifying biosimilars as part of its work to make some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
The first "Expression of Interest," according to WHO, will cover both rituximab (Roche’s Rituxan) and trastuzumab (Roche’s Herceptin), and will be published in October 2017.
In Europe, there are five centrally authorized rituximab biosimilars but no authorized trastuzumab biosimilars yet. In the US, an FDA panel recommended the approval of a Herceptin biosimilar in July (a final decision is expected 3 December), while Celltrion and Teva recently said FDA has accepted for review their biosimilar to rituximab.
"To provide clear guidance to manufacturers wishing to apply for the pilot project, WHO will be using two assessment pathways, for applicants with products approved by a stringent regulatory authority and for applications with products that were approved by other NRAs [national regulatory authorities]," WHO said.
The agency is also currently finalizing three guidance documents that will be used to assess biosimilars, including:
Questions can be submitted to: email@example.com.
Tags: biosimilar prequalification, WHO prequalification
Regulatory Focus newsletters
All the biggest regulatory news and happenings.